Article Versions Notes

Monteagudo V, Flores LCB, Lopes M, Fachel FNS, Martins G, Siebert M, Carniel WdS, Garcez TNA, Teixeira HF, Matte U, et al. Newborn Intravenous Injection of Liposomal CRISPR/Cas9 Complex Has No Incidence of Off-Targets or Tumors in Mice. Pharmaceutics. 2025; 17(5):656. https://doi.org/10.3390/pharmaceutics17050656

Monteagudo, Vinícius, Larissa Cristina Barbosa Flores, Melaine Lopes, Flavia Nathiely Silveira Fachel, Giselle Martins, Marina Siebert, Willian da Silva Carniel, Tuane Nerissa Alves Garcez, Helder Ferreira Teixeira, Ursula Matte, and et al. 2025. "Newborn Intravenous Injection of Liposomal CRISPR/Cas9 Complex Has No Incidence of Off-Targets or Tumors in Mice" Pharmaceutics 17, no. 5: 656. https://doi.org/10.3390/pharmaceutics17050656

Monteagudo, V., Flores, L. C. B., Lopes, M., Fachel, F. N. S., Martins, G., Siebert, M., Carniel, W. d. S., Garcez, T. N. A., Teixeira, H. F., Matte, U., Giugliani, R., Baldo, G., Poletto, É., & Schuh, R. S. (2025). Newborn Intravenous Injection of Liposomal CRISPR/Cas9 Complex Has No Incidence of Off-Targets or Tumors in Mice. Pharmaceutics, 17(5), 656. https://doi.org/10.3390/pharmaceutics17050656